Prioriteit geven aan doelgedrag voor onderzoek bij diabetes: de nominale groepstechniek gebruiken om consensus te bereiken van de belangrijkste belanghebbenden.

NIET TOEGEWEZEN Het gedrag van personen met diabetes (bijv. behandeling) en het gedrag van artsen en verschillende beroepsbeoefenaren in de gezondheidszorg (bijv. controle van de bloedsuikerspiegel van patiënten) zijn essentieel.

Onze onderzoeksgroep moest één gedrag van betrokkenen en één gedrag van bekwame zorgverleners kiezen als proefpersonen in Ierland. Patiënten en beroepsbeoefenaren in de gezondheidszorg worden meestal niet vaak gevraagd om te helpen bij het oplossen van onderzoeksonderwerpen.

In dit onderzoek moesten we collectief patiënten, zorgverleners en dekkingsmakers overbrengen om ons te helpen bij het oplossen van het meest essentiële doelgedrag voor onderzoek naar diabetes in Ierland. We werkten met 24 medewerkers, samen met mensen met diabetes, diabetesprofessionals en dekkingsmakers.

Ten eerste gaven de bijdragers instructies over gedragingen waarvan zij dachten dat ze essentieel waren voor onderzoek naar diabetes. Deelnemers woonden vervolgens een bijeenkomst bij en beoordeelden welk van de gedragingen het meest essentieel waren en noemden de resultaten van de ranglijst als een groep. We herkenden het meest extreem gerangschikte gedrag van getroffen personen en zorgverleners.

Het belangrijkste gerangschikte gedrag voor mensen met diabetes type 1 was ‘insuline nemen zoals vereist’ en voor mensen met diabetes type 2 was ‘het bijwonen van en interactie hebben met gestructureerde scholingsprogramma’s’. ‘Betrokkenheid bij het stellen van samenwerkingsdoelen met patiënten’ was het belangrijkste gedrag van zorgprofessionals.

Uit ons onderzoek blijkt dat het voor onderzoekers goed te doen is om samen te werken met mensen met diabetes, beroepsbeoefenaren in de gezondheidszorg en makers van dekkingen om onderzoeksonderwerpen op te lossen. De eerst gerangschikte gedragingen zullen nu worden onderzocht door onze groep in Ierland. UNASSIGNED Achtergrond Werken met patiënten, zorgverleners en dekkingsmakers om prioriteit te geven aan onderzoek onderwerpen kunnen de relevantie van onderzoek verbeteren en de kans vergroten dat onderzoeksresultaten worden omgezet in waarneming.

Het doel van het huidige onderzoek was om samen te werken met de belangrijkste belanghebbenden om te bepalen en consensus te bereiken over het meest essentiële doelgedrag voor onderzoek naar diabetes in Ierland. Methoden Vierentwintig bijdragers, samen met mensen met diabetes, diabetesprofessionals en dekkingsmakers, namen de helft in een nominale consensuscursus voor groepstechnieken.

Via een webgebaseerde enquête genereerden de bijdragers lijsten van essentieel doelgedrag op drie gebieden: diabetes type 1 beheren, diabetes type 2 beheren en diabetes type 2 stoppen.

Prioritising target behaviours for research in diabetes: Using the nominal group technique to achieve consensus from key stakeholders.
Prioritising target behaviours for research in diabetes: Using the nominal group technique to achieve consensus from key stakeholders.

Deelnemers woonden vervolgens een onderzoeksprioriteringsassemblage bij en rangschikten doelgedrag in twee rondes, met een groepsdialoog tussen beoordelingsrondes. Voor elk van de drie belangrijkste gebieden hadden de zes eerst gerangschikte gedragingen betrekking op mensen met diabetes en beroepsbeoefenaren in de gezondheidszorg zijn erkend.

Resultaten In de meeste gevallen was het meest extreem gerangschikte gedrag vergelijkbaar voor rangorde 1 en rangschikking 2 en was er een grotere consensus met betrekking tot het onderschrijven van eersteklas gedrag. Sommige gedragingen veranderden echter van plaats tussen ranglijsten.

Growth Blocking Peptide - I-125 Labeled

T-046-92 10 μCi
EUR 1145.88

40787 Blocking Peptide

33R-2900 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SEPT1 antibody, catalog no. 70R-9926

hCG_1982709 Blocking Peptide

33R-3437 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1982709 antibody, catalog no. 70R-9054

hCG_2042202 Blocking Peptide

33R-3770 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_2042202 antibody, catalog no. 70R-9063

hCG_1660138 Blocking Peptide

33R-4078 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1660138 antibody, catalog no. 70R-9044

hCG_1646157 Blocking Peptide

33R-4162 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1646157 antibody, catalog no. 70R-9034

hCG_20426 Blocking Peptide

33R-4753 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_20426 antibody, catalog no. 70R-8776

hCG_2007354 Blocking Peptide

33R-5366 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_2007354 antibody, catalog no. 70R-9061

hCG_20426 Blocking Peptide

33R-5875 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_20426 antibody, catalog no. 70R-8775

HCG_1745121 Blocking Peptide

33R-6558 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1745121 antibody, catalog no. 70R-3903

hCG_1646157 Blocking Peptide

33R-7420 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1646157 antibody, catalog no. 70R-9035

F7 Blocking Peptide

33R-1026 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DLG4 antibody, catalog no. 70R-4080

GC Blocking Peptide

33R-10350 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GC antibody, catalog no. 70R-10252

A1 Blocking Peptide

33R-10744 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of A1 antibody, catalog no. 70R-11802

KC Blocking Peptide

33R-11041 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KC antibody, catalog no. 70R-12298

F2 Blocking Peptide

33R-1783 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F2 antibody, catalog no. 70R-8514

PB Blocking Peptide

33R-2067 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of pb antibody, catalog no. 70R-2192

AC Blocking Peptide

33R-3003 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ac antibody, catalog no. 70R-1978

TH Blocking Peptide

33R-3167 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TH antibody, catalog no. 70R-7854

F8 Blocking Peptide

33R-3569 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F8 antibody, catalog no. 70R-9971

NP Blocking Peptide

33R-3631 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NP antibody, catalog no. 70R-2286

GC Blocking Peptide

33R-4418 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GC antibody, catalog no. 70R-10253

XK Blocking Peptide

33R-5017 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of XK antibody, catalog no. 70R-7169

SI Blocking Peptide

33R-5258 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SI antibody, catalog no. 70R-7230

GK Blocking Peptide

33R-5595 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GK antibody, catalog no. 70R-4533

TH Blocking Peptide

33R-6309 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TH antibody, catalog no. 70R-10442

HB Blocking Peptide

33R-6336 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hb antibody, catalog no. 70R-3198

N Blocking Peptide

33R-6561 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LSM8 antibody, catalog no. 70R-4590

SI Blocking Peptide

33R-6891 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SI antibody, catalog no. 70R-7205

XK Blocking Peptide

33R-7655 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of XK antibody, catalog no. 70R-7274

F7 Blocking Peptide

33R-7835 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F7 antibody, catalog no. 70R-9970

PC Blocking Peptide

33R-8614 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PC antibody, catalog no. 70R-9828

A1 Blocking Peptide

3401BP-50 each
EUR 183.6

C6 Blocking Peptide

DF3963-BP 1mg
EUR 234

C9 Blocking Peptide

DF3964-BP 1mg
EUR 234

MB Blocking Peptide

DF4194-BP 1mg
EUR 234

NT Blocking Peptide

DF4245-BP 1mg
EUR 234

PC Blocking Peptide

DF4364-BP 1mg
EUR 234

AR Blocking Peptide

DF6783-BP 1mg
EUR 234

MB Blocking Peptide

DF7358-BP 1mg
EUR 234

FH Blocking Peptide

DF7460-BP 1mg
EUR 234

F3 Blocking Peptide

DF6400-BP 1mg
EUR 234

HP Blocking Peptide

DF6467-BP 1mg
EUR 234

F9 Blocking Peptide

DF6474-BP 1mg
EUR 234

GK Blocking Peptide

DF3151-BP 1mg
EUR 234

C5 Blocking Peptide

DF7719-BP 1mg
EUR 234

GC Blocking Peptide

DF7840-BP 1mg
EUR 234

TG Blocking Peptide

DF7885-BP 1mg
EUR 234

F5 Blocking Peptide

DF8265-BP 1mg
EUR 234

Ob Blocking Peptide

DF8583-BP 1mg
EUR 234

ST Blocking Peptide

DF8616-BP 1mg
EUR 234

CP Blocking Peptide

DF9369-BP 1mg
EUR 234

C7 Blocking Peptide

DF9410-BP 1mg
EUR 234

OR Blocking Peptide

DF10250-BP 1mg
EUR 234

GK Blocking Peptide

AF0829-BP 1mg
EUR 234

GR Blocking Peptide

AF6066-BP 1mg
EUR 234

GR Blocking Peptide

AF6067-BP 1mg
EUR 234

TK Blocking Peptide

AF6068-BP 1mg
EUR 234

IR Blocking Peptide

AF6098-BP 1mg
EUR 234

IR Blocking Peptide

AF6099-BP 1mg
EUR 234

GR Blocking Peptide

AF5004-BP 1mg
EUR 234

KC Blocking Peptide

5212BP-50 each
EUR 183.6

T Blocking Peptide

BF0015-BP 1mg
EUR 234

AR Blocking Peptide

BF0418-BP 1mg
EUR 234

PR Blocking Peptide

BF0581-BP 1mg
EUR 234

RB Blocking Peptide

BF0614-BP 1mg
EUR 234

ER Blocking Peptide

BF0674-BP 1mg
EUR 234

E7 Blocking Peptide

BF0311-BP 1mg
EUR 234

TK Blocking Peptide

AF7678-BP 1mg
EUR 234

Rb Blocking Peptide

AF7698-BP 1mg
EUR 234

Ub Blocking Peptide

20-abx063395
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

FX Blocking Peptide

20-abx161511
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

GW Blocking Peptide

20-abx162574
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

PEPT1 Blocking Peptide

20-abx063272
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

Bax Blocking Peptide

3032BP-50 each
EUR 183.6

p53 Blocking Peptide

3036RBP-50 each
EUR 183.6

PBR Blocking Peptide

3044BP-50 each
EUR 183.6

Akt Blocking Peptide

3247BP-50 each
EUR 183.6

Bid Blocking Peptide

3272BP-50 each
EUR 183.6

RIP Blocking Peptide

3279BP-50 each
EUR 183.6

AT2 Blocking Peptide

30R-AA024 100 ug
EUR 195
Description: A synthetic AT2 Blocking peptide for use as a blocking control in assays to test for specificity of AT2 antibody, catalog no. 70R-AR006

NIK Blocking Peptide

3193RBP-50 each
EUR 183.6

AIF Blocking Peptide

3202BP-50 each
EUR 183.6

DR6 Blocking Peptide

3216RBP-50 each
EUR 183.6

DR4 Blocking Peptide

3061BP-50 each
EUR 183.6

DR5 Blocking Peptide

3062BP-50 each
EUR 183.6

PKA Blocking Peptide

3115BP-50 each
EUR 183.6

Bid Blocking Peptide

3172BP-50 each
EUR 183.6

BMF Blocking Peptide

3334RBP-50 each
EUR 183.6

OMP Blocking Peptide

33R-10003 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OMP antibody, catalog no. 70R-2611

FTO Blocking Peptide

33R-10037 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FTO antibody, catalog no. 70R-4523

F2R Blocking Peptide

33R-10057 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F2R antibody, catalog no. 70R-9967

MYB Blocking Peptide

33R-10068 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYB antibody, catalog no. 70R-8269

UST Blocking Peptide

33R-10095 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UST antibody, catalog no. 70R-1825

SDS Blocking Peptide

33R-1011 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DISC1 antibody, catalog no. 70R-2399

Gns Blocking Peptide

33R-10135 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Gns antibody, catalog no. 70R-8622

CNP Blocking Peptide

33R-10149 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CNP antibody, catalog no. 70R-1054

Utx Blocking Peptide

33R-10306 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Utx antibody, catalog no. 70R-7989

GBA Blocking Peptide

33R-10317 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GBA antibody, catalog no. 70R-10294

AK7 Blocking Peptide

33R-10319 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AK7 antibody, catalog no. 70R-10381

Mkx Blocking Peptide

33R-10329 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Mkx antibody, catalog no. 70R-8448

Zfr Blocking Peptide

33R-10340 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Zfr antibody, catalog no. 70R-8321

CCS Blocking Peptide

33R-10355 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CCS antibody, catalog no. 70R-10221

IDE Blocking Peptide

33R-10357 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IDE antibody, catalog no. 70R-7840

CAD Blocking Peptide

33R-1037 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RNASEN antibody, catalog no. 70R-4643

GP9 Blocking Peptide

33R-10371 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GP9 antibody, catalog no. 70R-10332

Tat Blocking Peptide

33R-10377 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Tat antibody, catalog no. 70R-8790

GCK Blocking Peptide

33R-10396 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GCK antibody, catalog no. 70R-10324

AGA Blocking Peptide

33R-10401 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AGA antibody, catalog no. 70R-10228

Bax Blocking Peptide

33R-10443 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bax antibody, catalog no. 20R-1435

p53 Blocking Peptide

33R-10444 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of p53 antibody, catalog no. 20R-1436

PKA Blocking Peptide

33R-10449 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PKA antibody, catalog no. 20R-1459

Bid Blocking Peptide

33R-10457 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bid antibody, catalog no. 20R-1486

Akt Blocking Peptide

33R-10462 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Akt antibody, catalog no. 20R-1501

ALK Blocking Peptide

33R-10471 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ALK antibody, catalog no. 20R-1521

AFX Blocking Peptide

33R-10484 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AFX antibody, catalog no. 20R-1555

PKC Blocking Peptide

33R-10494 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PKC antibody, catalog no. 20R-1581

Lck Blocking Peptide

33R-10503 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Lck antibody, catalog no. 20R-1612

FAH Blocking Peptide

33R-1054 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EPN1 antibody, catalog no. 70R-3618

JNK Blocking Peptide

33R-10543 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of JNK antibody, catalog no. 20R-1708

Brk Blocking Peptide

33R-10558 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Brk antibody, catalog no. 20R-1742

DUT Blocking Peptide

33R-1060 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UGCGL1 antibody, catalog no. 70R-4490

Bax Blocking Peptide

33R-10601 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bax antibody, catalog no. 70R-11570

p53 Blocking Peptide

33R-10604 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of p53 antibody, catalog no. 70R-11573

PBR Blocking Peptide

33R-10608 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PBR antibody, catalog no. 70R-11578

DR4 Blocking Peptide

33R-10613 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DR4 antibody, catalog no. 70R-11590

DR5 Blocking Peptide

33R-10614 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DR5 antibody, catalog no. 70R-11591

Rac Blocking Peptide

33R-10620 50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Rac antibody, catalog no. 70R-11597

Het belangrijkste gedrag gerelateerd aan mensen met diabetes type 1 was ‘insuline nemen zoals vereist’ en voor mensen met diabetes type 2 was ‘het bijwonen en fascineren met gestructureerde scholingsprogramma’s’. ‘Betrokkenheid bij het stellen van samenwerkingsdoelen met patiënten’ was het belangrijkste gerangschikte gedrag met betrekking tot beroepsbeoefenaren in de gezondheidszorg voor het beheren van elke type 1- en type 2-diabetes. Voor het stoppen van diabetes type 2 was ‘interactie hebben met gezond gedrag als huishouden’ het hoogst gerangschikte gedrag van de bewoners en ‘wonen en interactie hebben met coaching voor gedragsverandering’ was het hoogst bekwame gedrag.

Conclusies Het is mogelijk om samen te werken met een verschillende groep belanghebbenden om de onderzoeksagenda voor diabetes te informeren. De erkende prioriteiten zijn mede tot stand gekomen door de belangrijkste belanghebbenden, samen met patiënten, zorgverleners en dekkingsmakers, en kan de groei van een programma voor gedragsonderzoek bij diabetes in Ierland informeren.

Het onderzoek biedt bovendien een moeizaam voorbeeld van een cursus onderzoeksprioritering met gebruikmaking van de nominale groepstechniek en erkende beperkingen, die nuttig kunnen zijn voor verschillende onderzoekers.

Geef een antwoord

Het e-mailadres wordt niet gepubliceerd.